K
Kristine M. Kim
Researcher at Kangwon National University
Publications - 25
Citations - 1632
Kristine M. Kim is an academic researcher from Kangwon National University. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 13, co-authored 25 publications receiving 1518 citations. Previous affiliations of Kristine M. Kim include Fred Hutchinson Cancer Research Center & Seattle Genetics.
Papers
More filters
Journal ArticleDOI
Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.
Shie-Pon Tzung,Kristine M. Kim,Gorka Basañez,Chris D. Giedt,Julian A. Simon,Joshua Zimmerberg,Kam Y. J. Zhang,David M. Hockenbery +7 more
TL;DR: It is demonstrated that antimycin A and a Bak BH3 peptide bind competitively to recombinant Bcl-2, demonstrating that a small non-peptide ligand can directly inhibit the function of B cl-2-related proteins.
Journal ArticleDOI
Engineered antibody–drug conjugates with defined sites and stoichiometries of drug attachment
Charlotte Mcdonagh,Eileen Turcott,Lori Westendorf,Jennifer B. Webster,Stephen C. Alley,Kristine M. Kim,Jamie B. Andreyka,Ivan Stone,Kevin J. Hamblett,Joseph A. Francisco,Paul Carter +10 more
TL;DR: The engineered and parental antibody-drug conjugates have similar in vivo properties including antitumor activity, pharmacokinetics and maximum tolerated dose and are potentially broadly applicable to other antibodies as it involves engineering of constant domains.
Journal ArticleDOI
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Maureen Ryan,Michelle A. Hering,David Peckham,Charlotte Mcdonagh,Lindsay L. Brown,Kristine M. Kim,Damon L. Meyer,Roger F. Zabinski,Iqbal S. Grewal,Paul Carter +9 more
TL;DR: B-cell maturation antigen (BCMA) antibodies show cytotoxic activity both as naked IgG and as drug conjugates and warrant further evaluation as therapeutic candidates for plasma cell malignancies.
Journal ArticleDOI
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Eunhee G. Kim,Kristine M. Kim +1 more
TL;DR: The emergence of clinical antibody-drug conjugates, current trends in optimization strategies, and recent study results for antibody- drug conjugate that have incorporated the latest optimization strategies are discussed.
Journal ArticleDOI
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Charlotte Mcdonagh,Kristine M. Kim,Eileen Turcott,Lindsay L. Brown,Lori Westendorf,Tiffany Feist,Django Sussman,Ivan Stone,Martha Anderson,Jamie Miyamoto,Robert P. Lyon,Stephen C. Alley,Hans-Peter Gerber,Paul Carter +13 more
TL;DR: The IgG1v1 MMAF conjugate with MMAF displayed improved antitumor activity compared with other conjugates in 786-O and UMRC3 models of renal cell cancer and in the DBTRG05-MG glioblastoma model, and was tolerated to ≥40 mg/kg in mice.